Home Gritstone Oncology High-Risk IPO: Gritstone Oncology

High-Risk IPO: Gritstone Oncology

193
0

Gritstone Oncology focuses on cancer drugs—presently in pre-clinical trials. This focus is an extremely risky proposition, given the effort, cost, length of time and complexity that lies ahead as they move toward clinical trials. Read Seeking Alpha’s Donovan Jones for a nice summary of the situation for investors.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.